Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Peritoneal Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Cyclophosphamide 46fludarabine phosphate 40Tacrolimus 36Busulfan 34Peripheral Blood Stem Cell Transplantation 31Whole-Body Irradiation 29Mycophenolic Acid 27Antilymphocyte Serum 23Methotrexate 22Azacitidine 21Cyclosporine 20Cytarabine 17Melphalan 16Decitabine 16Radiotherapy 14fludarabine 13Methylprednisolone 12Filgrastim 12Cord Blood Stem Cell Transplantation 10Stem Cell Transplantation 8Etoposide 8Biopsy 8venetoclax 7Specimen Handling 7Rituximab 7Injections 7Arsenic Trioxide 7thymoglobulin 6merphos 6Sirolimus 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Myelomonocytic, Chronic × birinapant × Clear all
NCT02147873 2016-10-20

Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL

TetraLogic Pharmaceuticals

Phase 2 Terminated
118 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡